Single Arm on the Tolerability of Weekly Nab-paclitaxel
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Highlands Oncology Group
Fayetteville, Arkansas, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Rex Healthcare
Raleigh, North Carolina, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Bon Secours Virginia Health System
Midlothian, Virginia, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jun 2013
- Primary completion
- 23 Jun 2017
- Completion
- 12 Jul 2019
- Last update posted
- 8 Oct 2020
- Registered enrollment
- 42
- Registry id
- NCT01702844
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.